Last reviewed · How we verify
Lymphangiomatosis
Approved treatments
- Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Rapamune · Pfizer
Rapamune works by binding to the mTOR protein, inhibiting its activity and preventing the growth and proliferation of certain cells. - Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Lymphangiomatosis patent landscape — cliff calendar, originator estates, attackable patents
- Lymphangiomatosis treatment landscape brief
- Lymphangiomatosis treatment updates RSS
Frequently asked questions about Lymphangiomatosis
What drugs treat Lymphangiomatosis?
Tracked treatments include Rapamune, Rapamycin.
What is the treatment for Lymphangiomatosis?
Standard treatment for Lymphangiomatosis includes Rapamune, Rapamycin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Lymphangiomatosis patent cliff · Lymphangiomatosis CI report
- Treatment: Rapamune · Wyeth is now a wholly owned subsidiary of Pfizer
- Treatment: Rapamune · Pfizer
- Treatment: Rapamycin · Institut National de la Santé Et de la Recherche Médicale, France
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing